Switching to biosimilar infliximab (CT-P13): Evidence of clinical safety, effectiveness and impact on public health

Abraham, 2013, Developing oncology biosimilars: an essential approach for the future, Semin Oncol, 40, S5, 10.1053/j.seminoncol.2013.09.015 Rinaudo-Gaujous, 2013, Review article: biosimilars are the next generation of drugs for liver and gastrointestinal diseases, Aliment Pharmacol Ther, 38, 914, 10.1111/apt.12477 Haustein, 2012, Saving money in the European healthcare systems with biosimilars, Generics Biosimilars Initiat J, 1, 120, 10.5639/gabij.2012.0103-4.036 Rand corporation, 2014 EMA, 2014 FDA, 2015 WHO, 2009 GABI, 2011 Chow, 2013, Assessing biosimilarity and interchangeability of biosimilar products, Stat Med, 32, 316 FDA, 2015 Tóthfalusi, 2014, Statistical and regulatory considerations in assessments of interchangeability of biological drug products, Eur J Health Econ, 15, S5, 10.1007/s10198-014-0589-1 Ebbers, 2012, Interchangeability, immunogenicity and biosimilars, Nat Biotechnol, 30, 1186, 10.1038/nbt.2438 SCRIP, 2015 GABI, 2015 GABI, 2014 EBE, 2014 GABI, 2015 GABI, 2012 PEI, 2015 Grigor, 2004, Effect of a treatment strategy of tight control for rhuematoid arthritis (the TICORA study): a single-blind randomised controlled trial, Lancet, 23, 263, 10.1016/S0140-6736(04)16676-2 Goekoop-Ruiterman, 2005, Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial, Arthritis Rheum, 52, S126 Smolen, 2014, EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update, Ann Rheum Dis, 73, 492, 10.1136/annrheumdis-2013-204573 Mowat, 2011, Guidelines for the management of inflammatory bowel disease in adults, Gut, 60, 571, 10.1136/gut.2010.224154 Singh, 2012, 2012 update of the 2008 American college of rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis, Arthritis Care Res Hob, 64, 625, 10.1002/acr.21641 Van Assche, 2012, Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trial, Gut, 61, 229, 10.1136/gutjnl-2011-300755 Lie, 2011, Effectiveness of switching between TNF inhibitors in ankylosing spondylitis: data from the NOR-DMARD register, Ann Rheum Dis, 70, 157, 10.1136/ard.2010.131797 Bartelds, 2010, Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study, Ann Rheum Dis, 69, 817, 10.1136/ard.2009.112847 Jamnitski, 2011, The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept, Ann Rheum Dis, 70, 284, 10.1136/ard.2010.135111 Virkki, 2011, Outcomes of switching anti-TNF drugs in rheumatoid arthritis—a study based on observational data from the Finnish Register of Biological Treatment (ROB-FIN), Clin Rheumatol, 30, 1447, 10.1007/s10067-011-1779-1 Chatzidionysiou, 2015, Effectiveness of TNF inhibitor switch in RA: results from the national Swedish register, Ann Rheum Dis, 74, 890, 10.1136/annrheumdis-2013-204714 Fagerli, 2013, Switching between TNF inhibitors in psoriatic arthritis: data from the NOR-DMARD study, Ann Rheum Dis, 72, 1840, 10.1136/annrheumdis-2012-203018 Hyrich, 2007, Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study, Arthritis Rheum, 56, 13, 10.1002/art.22331 Harrold, 2015, The comparative effectiveness of abatacept versus anti-tumour necrosis factor switching for rheumatoid arthritis patients previously treated with an anti-tumour necrosis factor, Ann Rheum Dis, 74, 430, 10.1136/annrheumdis-2013-203936 Finckh, 2007, B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents, Arthritis Rheum, 56, 1417, 10.1002/art.22520 Gomez-Reino, 2012, Comparative effectiveness of switching to alternative tumour necrosis factor (TNF) antagonists versus switching to rituximab in patients with rheumatoid arthritis who failed previous TNF antagonists: the MIRAR study, Ann Rheum Dis, 71, 1861, 10.1136/annrheumdis-2012-201324 Kekow, 2012, Rituximab is more effective than second anti-TNF therapy in rheumatoid arthritis patients and previous TNFα blocker failure, Biologics, 6, 191 Blom, 2011, Effectiveness of a third tumor necrosis factor-α-blocking agent compared with rituximab after failure of 2 TNF- blocking agents in rheumatoid arthritis, J Rheumatol, 38, 2355, 10.3899/jrheum.101324 Navarro Coy, 2014, The 'Switch' study protocol: a randomised-controlled trial of switching to an alternative tumour-necrosis factor (TNF)-inhibitor drug or abatacept or rituxi mab in patients with rheumatoid arthritis who have failed an initial TNF-inhibitor drug, BMC Musculoskelet Disord, 15, 452, 10.1186/1471-2474-15-452 Weise, 2014, Biosimilars: the science of extrapolation, Blood, 124, 3191, 10.1182/blood-2014-06-583617 Devlin, 2013, Overview of subsequent entry biologics for the management of inflammatory bowel disease and Canadian Association of Gastroenterology position statement on subsequent entry biologics, Can J Gastroenterol, 27, 567, 10.1155/2013/327120 Feagan, 2014, The challenge of indication extrapolation for infliximab biosimilars, Biologicals, 42, 177, 10.1016/j.biologicals.2014.05.005 Maini, 1999, Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoidarthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group, Lancet, 354, 1932, 10.1016/S0140-6736(99)05246-0 Su, 2003, Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease, Gastroenterology, 125, 1544, 10.1016/j.gastro.2003.05.009 Anderson, 2005, Tumor necrosis factor inhibitors: clinical implications of their different immunogenicity profiles, Semin Arthritis Rheum, 34, 19, 10.1016/j.semarthrit.2005.01.005 Bendtzen, 2006, Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor α inhibitor infliximab, Arthritis Rheum, 54, 3782, 10.1002/art.22214 Wolbink, 2006, Development of anti-infliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis, Arthritis Rheum, 54, 711, 10.1002/art.21671 Yoo, 2013, A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study, Ann Rheum Dis, 72, 1613, 10.1136/annrheumdis-2012-203090 EMA, 2013 Ebbersa, 2012, The safety of switching between therapeutic proteins, Expert Opin Biol Ther, 12, 1473, 10.1517/14712598.2012.711308 Kropshofer, 2006, Overview of cell-based tools for pre-clinical assessment of immunogenicity of biotherapeutics, J Immunotoxicol, 3, 131, 10.1080/15476910600845625 Jawa, 2013, T-cell dependent immunogenicity of protein therapeutics: preclinical assessment and mitigation, Clin Immunol, 149, 534, 10.1016/j.clim.2013.09.006 Ben-Horin, 2015, Cross-immunogenicity: antibodies to infliximab in Remicade-treated patients with IBD similarly recognise the biosimilar Remsima, Gut Calvo, 2014, EU's new pharmacovigilance legislation: considerations for biosimilars, Drug Saf, 37, 125, 10.1007/s40264-013-0130-y McCamish, 2012, The state of the art in the development of biosimilars, Clin Pharmacol Ther, 91, 405, 10.1038/clpt.2011.343 Casadevall, 2013, Pharmacovigilance and biosimilars: considerations, needs and challenges, Expert Opin Biol Ther, 13, 1039, 10.1517/14712598.2013.783560 Ahmed, 2012, Biosimilars: impact of biologic product life cycle and european experience on the regulatory trajectory in the United States, Clin Ther, 34, 400, 10.1016/j.clinthera.2011.12.005 Vermeer, 2013, Traceability of biopharmaceuticals in spontaneous reporting systems: a cross-sectional study in the FDA adverse event reporting system (FAERS) and EudraVigilance databases, Drug Saf, 36, 617, 10.1007/s40264-013-0073-3 Flodmark, 2013, Switching from originator to Biosimilar human growth hormone using dialogue teamwork: single-center experience from Sweden, Biol Ther, 3, 35, 10.1007/s13554-013-0011-z Lefrère, 2011, First experience of autologous peripheral blood stem cell mobilization with biosimilar granulocyte colony-stimulating factor, Adv Ther, 28, 304, 10.1007/s12325-011-0009-1 Ianotto, 2012, Experience (1 year) of G-CSF biosimilars in PBSCT for lymphoma and myeloma patients, Bone Marrow Transpl, 47, 874, 10.1038/bmt.2011.189 Publicover, 2013, Use of a biosimilar granulocyte colony-stimulating factor for peripheral blood stem cell mobilization: an analysis of mobilization and engraftment, Br J Haematol, 162, 107, 10.1111/bjh.12345 Gascón, 2013, Clinical experience with Zarzio® in Europe: what have we learned?, Support Care Cancer, 21, 2925, 10.1007/s00520-013-1911-7 EMA, 2007 EMA, 2007 Haag-Weber, 2009, Therapeutic equivalence, long-term efficacy and safety of HX575 in the treatment of anemia in chronic renal failure patients receiving hemodialysis, Clin Nephrol, 72, 380 Wizemann, 2008, Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment, Curr Med Res Opin, 24, 625, 10.1185/030079908X273264 Davis-Ajami, 2014, Epoetin zeta in the management of anemia associated with chronic kidney disease, differential pharmacology and clinical utility, Biologics, 8, 155 Więcek, 2010, Switching epoetin alfa and epoetin zeta in patients with renal anemia on dialysis: posthoc analysis, Adv Ther, 27, 941, 10.1007/s12325-010-0080-z Hörbrand, 2013, A population-based study comparing biosimilar versus originator erythropoiesis-stimulating agent consumption in 6,117 patients with renal anaemia, Eur J Clin Pharmacol, 69, 929, 10.1007/s00228-012-1412-5 Jung, 2014, Physicochemical characterization of Remsima, MAbs, 6, 1163, 10.4161/mabs.32221 Park, 2013, A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study, Ann Rheum Dis, 72, 1605, 10.1136/annrheumdis-2012-203091 Takeuchi, 2015, Evaluation of the pharmacokinetic equivalence and 54-week efficacy and safety of CT-P13 and innovator infliximab in Japanese patients with rheumatoid arthritis, Mod Rheumatol, 25, 817, 10.3109/14397595.2015.1022297 Yoo, 2013, Efficacy and safety of CT-P13 (infliximab biosimilar) over two years in patients with rheumatoid arthritis: comparison between continued CT-P13 and switching from infliximab to CT-P13, Arthritis Rheum, 65, 3319 Park, 2013, Efficacy and safety of CT-P13 (infliximab biosimilar) over two years in patients with ankylosing spondylitis: comparison between continuing with CT-P13 and switching from infliximab to CT-P13, Arthritis Rheum, 65, 3326 Brown, 2016, Efficacy and safety of switching from reference infliximab to CT-P13 compared to maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS, Arthritis Rheum Jung, 2015, Efficacy and safety of CT-P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: a retrospective multicenter study, J Gastroenterol Hepatol, 10.1111/jgh.12997 Park, 2015, Post-marketing study of biosimilar infliximab (CT-P13) to evaluate its safety and efficacy in Korea, Expert Rev Gastroenterol Hepatol, 9, 35, 10.1586/17474124.2015.1091309 Kang, 2015, Clinical experience of the use of CT-P13, a Biosimilar to Infliximab in patients with inflammatory Bowel disease: a case series, Dig Dis Sci, 60, 951, 10.1007/s10620-014-3392-z Joanna, 2015, Switching between infliximab originator and biosimilar in pediatric patients with inflammatory bowel disease. Preliminary observation, J Crohns Colitis Nikiphorou, 2015, Clinical effectiveness of CT-P13 (Infliximab biosimilar) used as a switch from Remicade (infliximab) in patients with established rheumatic disease. Report of clinical experience based on prospective observational data, Expert Opin Biol Ther, 15, 1677, 10.1517/14712598.2015.1103733 BioPharma Danese, 2014, Viewpoint: knowledge and viewpoints on biosimilar monoclonal antibodies among members of the European Crohn's and Colitis Organization, J Crohns Colitis, 8, 1548, 10.1016/j.crohns.2014.06.007 Fonseca, 2014, The Portuguese Society of Rheumatology position paper on the use of biosimilars, Acta Reumatol Port, 39, 60 Mularczyk, 2014, Biosimilar medicines – their use in the treatment of inflammatory bowel diseases. Position statement of the working group of the Polish National Consultant in Gastroenterology, Prz Gastroenterol, 9, 1 Zelenetz, 2011, NCCN Biosimilars white paper: regulatory, scientific, and patient safety perspectives, J Natl Compr Canc Netw, 9, S1 Jahnsen, 2015, Biosimilar infliximab (CT-P13) in the treatment of inflammatory bowel disease: a Norwegian observational study, Expert Rev Gastroenterol Hepatol, 9, 45, 10.1586/17474124.2015.1091308 Gecse, 2015, Efficacy and safety of the Biosimilar Infliximab CT-P13 treatment in inflammatory bowel diseases: a prospective, multicentre, nationwide cohort, J Crohns Colitis GABI, 2015 Gulácsi, 2015, Biosimilars for the management of rheumatoid arthritis: economic considerations, Expert Rev Clin Immunol, 11, S43, 10.1586/1744666X.2015.1090313 Jha, 2015, The budget impact of biosimilar infliximab (Remsima®) for the treatment of autoimmune diseases in five European countries, Adv Ther, 32, 742, 10.1007/s12325-015-0233-1 Brodszky, 2015, A budget impact model for biosimilar infliximab in Crohn's disease in Bulgaria, the Czech Republic, Hungary, Poland, Romania and Slovakia, Expert Rev Pharmacoecon Outcomes Res, 1, 10.1586/14737167.2015.1067142 Kim, 2014, 5 year budget impact analysis of biosimilar infliximab for the treatment of rheumatoid arthritis in UK, Italy, France and Germany Brodszky, 2014, Budget impact analysis of biosimilar infliximab (CT-P13) for the treatment of rheumatoid arthritis in six Central and Eastern European countries, Eur J Health Econ, 15, S65, 10.1007/s10198-014-0595-3 Baji, 2016, Treatment preferences of originator vs. biosimilar drugs in Crohn's disease; discrete choice experiment among gastroenterologists, Scand J Gastroenterol, 51, 22, 10.3109/00365521.2015.1054422 Rencz, 2015, Biological therapy in inflammatory bowel diseases: access in Central and Eastern Europe, World J Gastroenterol, 21, 1728, 10.3748/wjg.v21.i6.1728 McCarthy, 2013, Introduction of an infliximab biosimilar (CT-P13): a five-year budget impact analysis for the treatment of rheumatoid arthritis in Ireland, Value Health, 16, A558, 10.1016/j.jval.2013.08.1465 NICE, 2015 NICE, 2015